MedTrace Logo

CIPN and it's Impact on Quality of Life in Patients Receiving Platinum and Taxanes

NCT05829967 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2023-04-26

No results posted yet for this study

Summary

Neuropathies are a major cause of moderate to severe impairments in cancer patients.

Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent side effects caused by antineoplastic agents, with a prevalence from 19% to over 85%.

Conditions

  • Chemotherapy-induced Peripheral Neuropathy

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Taha Zaki, Prof · Assiut University

  • Mohamed Alaa El Deen, Assist prof · Assiut University

  • Samar El Morshidy, Assist prof · Assiut University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2024-06-01
Completion
2024-08-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05829967 on ClinicalTrials.gov